

Special Issue

Genetics and Epigenetics of Leukemia and Lymphoma

Message from the Guest Editor

Recent technological advances in the field of next-generation sequencing and chromatin conformation together with refined computational tools have greatly advanced our understanding of genetic and epigenetic alterations, leading to the establishment of new treatments to treat cancer. For this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- Genetic and epigenetic alterations in hematological disease;
- Novel mechanisms of gene regulation via DNA and RNA modifications (including DNA/RNA methylation, histone modifications, RNA alternative splicing and noncoding RNAs);
- Molecular mechanisms governing gene expression at the genetic and epigenetic level and strategies for their reversibility;
- Computational approaches for the analysis of genetic and epigenetic mechanisms in cancer;
- Genetic and epigenetic alterations in response to environmental factors and drugs;
- Molecular profiling of genetic and epigenetic markers for the discovery of biomarkers and therapeutic targets.

Guest Editor

Dr. Francesco E. Boccalatte

The Aifantis Lab, NYU Grossman School of Medicine, New York, NY, USA

Deadline for manuscript submissions

closed (23 November 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/158792

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)